These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 23283747)

  • 1. Gene therapy enters the pharma market: the short story of a long journey.
    Büning H
    EMBO Mol Med; 2013 Jan; 5(1):1-3. PubMed ID: 23283747
    [No Abstract]   [Full Text] [Related]  

  • 2. The Bespoke Gene Therapy Consortium: facilitating development of AAV gene therapies for rare diseases.
    Brooks PJ; Miller TM; Revah F; Suh J; Garrison BR; Starke LC; MacLachlan TK; Neilan EG; Raychaudhuri G; Kassim SH; Dehdashti J; Rutter JL
    Nat Rev Drug Discov; 2024 Mar; 23(3):157-158. PubMed ID: 38321319
    [No Abstract]   [Full Text] [Related]  

  • 3. Gene therapies start the climb from rare disease base camps to common disease peaks.
    Mullard A
    Nat Rev Drug Discov; 2024 Aug; 23(8):574-576. PubMed ID: 38918582
    [No Abstract]   [Full Text] [Related]  

  • 4. 'Bespoke Gene Therapy Consortium' sets out to enable gene therapies for ultra-rare diseases.
    Kingwell K
    Nat Rev Drug Discov; 2021 Dec; 20(12):886-887. PubMed ID: 34773079
    [No Abstract]   [Full Text] [Related]  

  • 5. Access to gene therapy for rare diseases when commercialization is not fit for purpose.
    Fox T; Bueren J; Candotti F; Fischer A; Aiuti A; Lankester A; ; Booth C
    Nat Med; 2023 Mar; 29(3):518-519. PubMed ID: 36782029
    [No Abstract]   [Full Text] [Related]  

  • 6. Ensuring a future for gene therapy for rare diseases.
    Aiuti A; Pasinelli F; Naldini L
    Nat Med; 2022 Oct; 28(10):1985-1988. PubMed ID: 35970921
    [No Abstract]   [Full Text] [Related]  

  • 7. Realizing the Potential of Gene Therapies for Rare and Ultra-Rare Inherited Diseases.
    Booth C; Aiuti A
    Hum Gene Ther; 2023 Sep; 34(17-18):776-781. PubMed ID: 37624746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are we prepared to deliver gene-targeted therapies for rare diseases?
    Yu TW; Kingsmore SF; Green RC; MacKenzie T; Wasserstein M; Caggana M; Gold NB; Kennedy A; Kishnani PS; Might M; Brooks PJ; Morris JA; Parisi MA; Urv TK
    Am J Med Genet C Semin Med Genet; 2023 Mar; 193(1):7-12. PubMed ID: 36691939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The long journey of people with rare diseases: from darkness to the UN Resolution 2021. Editorial.
    Taruscio D
    Ann Ist Super Sanita; 2022; 58(2):79-80. PubMed ID: 35722792
    [No Abstract]   [Full Text] [Related]  

  • 10. Topical herpesvirus gene therapy enters final lap.
    Sheridan C
    Nat Biotechnol; 2022 Jun; 40(6):809-811. PubMed ID: 35705715
    [No Abstract]   [Full Text] [Related]  

  • 11. Promoting expression in gene therapy: more is not always better.
    Zwartkruis MM; Groen EJ
    EMBO Mol Med; 2024 Apr; 16(4):672-674. PubMed ID: 38413837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Precise genome-editing in human diseases: mechanisms, strategies and applications.
    Zheng Y; Li Y; Zhou K; Li T; VanDusen NJ; Hua Y
    Signal Transduct Target Ther; 2024 Feb; 9(1):47. PubMed ID: 38409199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-canonical amino acid incorporation into AAV5 capsid enhances lung transduction in mice.
    Chang H; Du A; Jiang J; Ren L; Liu N; Zhou X; Liang J; Gao G; Wang D
    Mol Ther Methods Clin Dev; 2023 Dec; 31():101129. PubMed ID: 37886602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of new adeno-associated virus capsid variants for targeted gene delivery to human cardiomyocytes.
    Kok CY; Tsurusaki S; Cabanes-Creus M; Igoor S; Rao R; Skelton R; Liao SHY; Ginn SL; Knight M; Scott S; Mietzsch M; Fitzsimmons R; Miller J; Mohamed TMA; McKenna R; Chong JJH; Hill AP; Hudson JE; Alexander IE; Lisowski L; Kizana E
    Mol Ther Methods Clin Dev; 2023 Sep; 30():459-473. PubMed ID: 37674904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune Responses to Muscle-Directed Adeno-Associated Viral Gene Transfer in Clinical Studies.
    Kumar SRP; Duan D; Herzog RW
    Hum Gene Ther; 2023 May; 34(9-10):365-371. PubMed ID: 37154743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complement Activation by Adeno-Associated Virus-Neutralizing Antibody Complexes.
    West C; Federspiel JD; Rogers K; Khatri A; Rao-Dayton S; Ocana MF; Lim S; D'Antona AM; Casinghino S; Somanathan S
    Hum Gene Ther; 2023 Jun; 34(11-12):554-566. PubMed ID: 37082966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR/Cas systems usher in a new era of disease treatment and diagnosis.
    Li R; Wang Q; She K; Lu F; Yang Y
    Mol Biomed; 2022 Oct; 3(1):31. PubMed ID: 36239875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential Applications for Targeted Gene Therapy to Protect Against Anthracycline Cardiotoxicity:
    Kok CY; MacLean LM; Ho JC; Lisowski L; Kizana E
    JACC CardioOncol; 2021 Dec; 3(5):650-662. PubMed ID: 34988473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemical modification of the adeno-associated virus capsid to improve gene delivery.
    Mével M; Bouzelha M; Leray A; Pacouret S; Guilbaud M; Penaud-Budloo M; Alvarez-Dorta D; Dubreil L; Gouin SG; Combal JP; Hommel M; Gonzalez-Aseguinolaza G; Blouin V; Moullier P; Adjali O; Deniaud D; Ayuso E
    Chem Sci; 2019 Dec; 11(4):1122-1131. PubMed ID: 34084369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nucleic Acid Delivery with Red-Blood-Cell-Based Carriers.
    Della Pelle G; Kostevšek N
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34067699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.